Amber Therapeutics
Created in 2021
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
3,226Activities
Technologies
Entity types
Location
242 Acklam Rd, London W10 5JJ, UK
London
United Kingdom
Employees
Scale: 11-50
Estimated: 33
Engaged corporates
2
2 0Added in Motherbase
1 year, 7 months ago
deeptech Value proposition
Doing the extraordinary to restore the ordinary
Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. With the acquisition of Finetech Medical Limited and Bioinduction Ltd in 2023, we are continuing to be the only UK based company in the field of designing and manufacturing long-term implantables.
We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation.
Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.
Amber Therapeutics - Home
Doing the extraordinary to restore the ordinary. We’re developing the first adaptive neuromodulation therapy that is able to treat women suffering with mixed incontinence.
https://www.amber-tx.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 31 Jul 2024 | | |
 Oxford University Innovation Research, Financial Services | Oxford University Innovation Research, Financial Services | Other 24 Jul 2024 | | |